Your browser doesn't support javascript.
loading
Integrated system for detection and molecular characterization of circulating tumor cells.
Takahashi, Yusuke; Shirai, Kentaro; Ijiri, Yuichi; Morita, Eri; Yoshida, Tomokazu; Iwanaga, Shigeki; Yanagida, Masatoshi.
  • Takahashi Y; Department of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
  • Shirai K; Department of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
  • Ijiri Y; Department of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
  • Morita E; Department of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
  • Yoshida T; Department of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
  • Iwanaga S; Department of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
  • Yanagida M; Department of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
PLoS One ; 15(8): e0237506, 2020.
Article en En | MEDLINE | ID: mdl-32790768
Circulating tumor cells (CTCs) invade blood vessels in solid tumors and promote metastases by circulating in the blood. CTCs are thus recognized as targets for liquid biopsy and can provide useful information for design of treatments. This diagnostic approach must consider not only the number of CTCs but also their molecular and genetic characteristics. For this purpose, use of devices that enrich CTCs independent of these characteristics and detectors that recognize various CTC characteristics is essential. In the present study, we developed a CTC detection system comprising ClearCell FX and ImageStream Mark II. We clarified the analytical performance of this system by evaluating recovery rate, lower limits of detection, and linearity. These parameters are critical for detecting rare cells, such as CTCs. We tested these parameters using three cell lines with different expression levels of the epithelial marker-epithelial cell adhesion molecule (EpCAM) and spiked these cells into whole-blood samples from healthy donors. The average recovery rate and lower limit of detection were approximately 40% and five cells/7.5 mL of whole blood, respectively. High linearity was observed for all evaluated samples. We also evaluated the ability of the system to distinguish between normal and abnormal cells based on protein expression levels and gene amplification and found that the system can identify abnormal cells using these characteristics. The CTC detection system thus displays the ability to distinguish specific characteristics of CTC, thereby providing valuable information for cancer treatment.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Células Neoplásicas Circulantes / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Células Neoplásicas Circulantes / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article